Next-Generation Sequencing Reveals a Very Low Prevalence of Deleterious Mutations of Homologous Recombination Repair Genes and Homologous Recombination Deficiency in Ovarian Clear Cell Carcinoma

被引:4
|
作者
Liu, Hangqi [1 ]
Zhang, Zhiwen [1 ]
Chen, Longyun [1 ]
Pang, Junyi [1 ]
Wu, Huanwen [1 ]
Liang, Zhiyong [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Mol Pathol Res Ctr, Dept Pathol,State Key Lab Complex Severe & Rare D, Beijing, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2022年 / 11卷
基金
中国国家自然科学基金;
关键词
ovarian clear cell carcinoma; homologous recombination repair gene; homologous recombination deficiency; molecular classification; next-generation sequencing; EXPRESSION; VARIANTS;
D O I
10.3389/fonc.2021.798173
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ovarian clear cell carcinoma (OCCC) is aggressive and drug-resistant. The prevalence of homologous recombination repair (HRR) gene mutations and homologous recombination deficiency (HRD) remains largely unknown. It is also not clear whether the commonly used molecular-based classification for endometrial carcinoma (EC) is potentially applicable in OCCC. In this study, surgically resected samples were collected from 44 patients with OCCC. Genomic alterations were determined using next-generation sequencing. HRD was estimated by genomic instability. Of 44 patients with OCCC, two (4.5%) harbored likely pathogenic mutations in HRR genes. Notably, no pathogenic or likely pathogenic mutations were found in BRCA1/2. A total of 24 variants of uncertain significance (VUS) in HRR-related genes occurred in 18 (40.9%) patients. HRD was observed in only one case (2.3%). In addition, TP53 mutation and microsatellite instability-high (MSI-H) were identified in three patients (6.8%) and in one patient (2.3%), respectively. TP53 mutation was significantly associated with disease-free survival and overall survival. No POLE mutations were found. In conclusion, our results revealed a very low prevalence of HRR gene mutations and HRD in OCCC. Moreover, TP53 mutations and MSI-H are uncommon, while POLE mutations are extremely rare in OCCC. Our findings indicate that the evaluation of HRR gene mutations, HRD status, POLE mutations, and MSI-H may have limited clinical significance for OCCC treatment and prognostic stratification.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] GENOMIC SCAR SIGNATURES ASSOCIATED WITH HOMOLOGOUS RECOMBINATION DEFICIENCY PREDICT ADVERSE CLINICAL OUTCOMES IN PATIENTS WITH OVARIAN CLEAR CELL CARCINOMA
    Chao, A.
    Lai, C. H.
    Ku, F. C.
    Chang, T. C.
    Ren-Chin, W.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 139 - 139
  • [22] Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinoma
    Angel Chao
    Chyong-Huey Lai
    Tzu-Hao Wang
    Shih-Ming Jung
    Yun-Shien Lee
    Wei-Yang Chang
    Lan-Yang Yang
    Fei-Chun Ku
    Huei-Jean Huang
    An-Shine Chao
    Chin-Jung Wang
    Ting-Chang Chang
    Ren-Chin Wu
    Journal of Molecular Medicine, 2018, 96 : 527 - 536
  • [23] Detection of homologous recombination deficiency (HRD) in cell-free DNA (cfDNA) using an amplicon-based next-generation sequencing (NGS) assay
    Poh, Jonathan
    Kaur, Harvinder
    Ho, Jia Min
    Choudhury, Yukti
    Tan, Min-Han
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] Homologous Recombination Abnormalities Associated With BRCA1/2 Mutations as Predicted by Machine Learning of Targeted Next-Generation Sequencing Data
    Albitar, Maher
    Zhang, Hong
    Pecora, Andrew
    Waintraub, Stanley
    Graham, Deena
    Hellmann, Mira
    Mcnamara, Donna
    Charifa, Ahmad
    De Dios, Ivan
    Ma, Wanlong
    Goy, Andre
    BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2023, 17
  • [25] Analytical Performance of a Next-Generation Sequencing (NGS) Assay Kit for Assessing Homologous Recombination Deficiency (HRD) from Solid Tumor Samples
    Liu, L.
    Roessler, K.
    Bilke, S.
    Ding, Y.
    Erlandson, D.
    Fu, Y.
    Hariharan, B.
    Katz, S.
    Lee, J.
    Schulman, C.
    Song, F.
    Vijayaraghavan, R.
    Wenz, P.
    Xia, E.
    Yan, H.
    Zhu, Y.
    Zhao, C.
    Dockter, J.
    Pawlowski, T.
    Day, J.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2022, 24 (10): : S91 - S91
  • [26] Analytical performance of a next-generation sequencing (NGS) assay kit for assessing homologous recombination deficiency (HRD) from solid tumor samples
    Liu, L.
    Roessler, K.
    Bilke, S.
    Ding, Y.
    Erlandson, D.
    Fu, Y.
    Hariharan, B.
    Katz, S.
    Lee, J.
    Schulman, C.
    Song, F.
    Vijayaraghavan, R.
    Wenz, P.
    Xia, E.
    Yan, H.
    Zhu, Y.
    Zhao, C.
    Dockter, J.
    Pawlowski, T.
    Day, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S969 - S969
  • [27] Identification of gene mutations in ovarian clear cell carcinoma by next generation sequencing
    Tanaka, N.
    Maru, Y.
    Suzuka, K.
    Ijiri, M.
    Hippo, Y.
    Nagase, H.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 840 - 840
  • [28] Pan-cancer Analysis of Tumor Mutational Burden and Homologous Recombination DNA Damage Repair Using Targeted Next-Generation Sequencing
    Wang, Hai-Yun
    Deng, Ling
    Li, Ying-Qing
    Zhang, Xiao
    Long, Ya-Kang
    Zhang, Xu
    Feng, Yan-Fen
    He, Yuan
    Tang, Tao
    Yang, Xin-Hua
    Wang, Fang
    CANCER RESEARCH AND TREATMENT, 2021, 53 (04): : 973 - 982
  • [29] Next-generation sequencing of homologous recombination genes could predict efficacy of platinum-based chemotherapy in non-small cell lung cancer
    Zhang, Linlin
    Guan, Shasha
    Meng, Fanlu
    Teng, Lin
    Zhong, Diansheng
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [30] Homologous recombination mutations and overall survival in high-grade serous, endometrioid, and clear cell ovarian carcinomas
    Harrell, Maria I.
    Maurer, Matthew J.
    Heinzen, Ethan P.
    Lee, Ming K.
    Kalli, Kimberly R.
    Agnew, Kathy J.
    Oberg, Ann L.
    Walsh, Tom
    Norquist, Barbara M.
    Hartmann, Lynn C.
    Kaufmann, Scott H.
    Swisher, Elizabeth M.
    CLINICAL CANCER RESEARCH, 2016, 22